Biotech Analyst Karnauskas, along with Dr. Anton Porsteinsson, discuss the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) impact on Leqembi (Eisai & Biogen) on an Analyst/Industry conference call to be held on April 12 at 9:45 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biogen exercises option with Denali to develop its ATV:ABeta program
- Biogen price target lowered to $349 from $351 at Morgan Stanley
- Biogen price target lowered to $307 from $310 at Barclays
- Truist biotechnology analyst to hold an analyst/industry conference call
- Drugmakers call for abortion pill ruling reversal, Reuters reports